According to Nova one advisor, the global Mice Model Technologies market was valued at USD 2.6 billion in 2021 and it is expected to hit around USD 6.2 billion by 2030 with a CAGR of 7.40% during the forecast period 2022 to 2030.
Animal model is a non-human species, which can mimic characteristics of a biological process or a disease found in humans. Animal models are used in biomedical research. Genetic engineering is used to develop different types of mice models to target specific human diseases. Mice model technologies are often adopted in biomedical research, as mice share mammalian features with humans and suffer from many similar diseases.
Report Scope of the Mice Model Technologies Market
Surge in Investment in Biomedical Research to Drive Demand for Mice Model Technologies
Investment in biomedical research is considered one of the most important indicators of any country’s research landscape. In the last decade, biomedical research expenditure has increased manifold across the globe, with developed countries such as the U.S. and the U.K. dominating the landscape. Majority of these investments are made for R&D of animal models.
The National Institutes of Health (NIH), the largest advocate of biomedical research in the world, had a budget of around US$ 31 Bn in 2019, followed by the Bill & Melinda Gates Foundation (BMGF) and the Wellcome Trust (each with approximately US$ 1.08 Bn; 3.1%). Overall, around 89.6% (approximately US$ 32 Bn) of all the grants awarded for biomedical research were allocated to recipient organizations in the U.S. More than 60% of NIH extramural funding involves animal-related research; most of this is allocated to mice-related studies. Thus, increase in biomedical research funding is expected to drive the global mice model technologies market during the forecast period.
Rise in Adoption of Advanced Genomic Techniques
Various techniques and methodologies have been developed in the past few years to create genetically modified mice models of human diseases. Homologous recombination in embryonic stem cells is the conventional way of gene targeting. The advent of new molecular genome-altering technologies such as CRISPR/Cas9 allows for genetic mutations to be introduced into the germ line of a mouse faster and cheaper than previous methods.
Development of mice models is significantly easier than before with the use of CRISPR-based techniques. These techniques can be employed to effectively and quickly (within two to three months) produce frequently used mice models (simple knockout mouse, CRISPR Knockin mouse, point mutation knock-in mouse, cKOs, and reporter/Cre knock-ins). One or two guide RNAs and Cas9 protein can be injected to generate knockout mice. Development of large knock-ins (approximately 5 to 10 kb long) is generally achieved using plasmid DNAs as donors. CRISPR editing or ESC-mediated gene targeting can be used to create humanized knock-in (KI) mice models; each technique has its advantages for model development.
Cyagen TurboKnockout gene targeting service combines benefits of each approach to enable sophisticated gene modeling in C57BL/6 or BALB/c mouse models on an accelerated timeframe, including LFKIs up to 300 kb. In as little as six months, TurboKnockout can provide research-ready mouse models for humanization.
High Efficiency of CRISPR Gene Editing Technology Boosting CRISPR Knockout Segment
In terms of technology, the global mice model technologies market has been segregated into CRISPR Knockout; CRISPR Knockin; random insertions, large, targeted insertions; ES cell modification (homologous recombination); and others. The CRISPR Knockout segment held dominant share of the market in 2021. It is expected to maintain its dominance during the forecast period. Growth of the segment can be ascribed to high efficiency of CRISPR gene editing technology and increase in adoption of CRISPR technology for the development of CRISPR Knockout mice.
Increase in Adoption of CRISPR Technology in Biotechnology Companies
Based on end-user, the global mice model technologies market has been classified into pharmaceutical companies, biotechnology companies, academic and research facilities, and contract research and manufacturing organizations.
The biotechnology companies segment is projected to account for dominant share of the global mice model technologies market during the forecast period. Increase in adoption of CRISPR technology in biotechnology companies and research laboratories is driving the segment. For instance, in October 2016, Caribou Biosciences granted The Jackson Laboratory non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically-engineered mice for research purposes.
The academic and research facilities segment is expected to grow at a higher rate during the forecast period. Growth of the segment can be ascribed to the rise in funding for academic and research facilities for R&D in mice model technologies.
Regional Outlook of Global Mice Model Technologies Market
North America dominated the global mice model technologies market, with more than 40% share in 2021. According to the mice model technologies market research study, rise in research and development activities in CRISPR to provide modified products for prevention and treatment of various chronic and rare diseases, such as sickle cell anemia and Alzheimer’s diseases, is expected to fuel the market in North America in the near future.
Asia Pacific is also poised to witness significant growth during the forecast period, owing to the increase in adoption of mice models for R&D in COVID-19 prevention and treatment.
Key Developments in Global Mice Model Technologies Market
- In July 2022, GemPharmatech announced that it had entered into a strategic license agreement with Charles River Laboratories, Inc. for exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America
- In March 2022, Charles River Laboratories signed an agreement to breed, distribute, market, and sell Hera BioLabs' SRG rat to the global preclinical research community. Unlike other immunodeficient rodent strains such as the nude rat, the SRG (Sprague Dawley, Rag2, Il2rg-"SRG") is a severely immunodeficient model created through knockout mutations in the Rag2 and Il2r gamma genes that results in mature B, T, and NK cell deficiencies. This severe immunodeficiency, combined with a larger organism size, makes the SRG rat an ideal alternative research model to mice in certain preclinical applications.
- In May 2021, the La Jolla Institute for Immunology (LJI) entered into a partnership agreement with Synbal, Inc. to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI is expected to be led by Professor Shresta. By combining Synbal’s proprietary gene-editing platform called Active Genetics with Shresta’s expertise in the characterization of immune responses to emerging and re-emerging viral pathogens, the team plans to develop several humanized mouse models to study Covid-19.
- In May 2020, Oragenics, Inc. announced that it had entered into an agreement with Aragen Bioscience to advance TerraCov2, the company’s SARS CoV-2 vaccine candidate, through Noachis Terra, its wholly-owned subsidiary. As per the terms of the agreement, Aragen will provide cell line development services to Oragenics to aid in the development of TerraCoV2, which could provide specific immunity from the novel coronavirus, the root cause of Covid-19.
- In March 2019, Charles River Laboratories inked a licensing deal with Crown Bioscience, a drug discovery and development services provider, for expanded access to the Zucker Diabetic Sprague-Dawley (ZDSD) rat model. As per the deal, Charles River gets an exclusive license to breed and distribute the ZDSD model. In return, Crown Bio is guaranteed a premium-quality and prioritized supply of ZDSD models to support its service platforms.
- In December 2018, Merck announced a strategic alliance in the CRISPR/Cas9 rodent model market with genOway, a France-based biotechnology company
Some of the prominent players in the Mice Model Technologies Market include:
- BIOCYTOGEN
- Charles River Laboratories
- Cyagen Biosciences
- Gempharmatech
- genOway
- ingenious targeting laboratory
- Merck KGaA
- Ozgene Pty Ltd.
- Taconic Biosciences, Inc.
- PolyGene AG
- THE JACKSON LABORATORY
- Yale School of Medicine
- University of North Carolina
- University of Nebraska Medical Center
- Monash University
- UMass Chan Medical School
- University of Bonn
- Columbia University
- The University of Arizona
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Mice Model Technologies market
- Technology
- CRISPR Knockout
- CRISPR Knockin
- Random Insertions
- Large, Targeted Insertions
- ES Cell Modification (Homologous Recombination)
- Others
- End-user
- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Facilities
- Contract Research and Manufacturing Organizations
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Mice Model Technologies industry analysis from 2022 to 2030 to identify the prevailing Mice Model Technologies industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global Mice Model Technologies industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Mice Model Technologies industry trends, key players, market segments, application areas, and market growth strategies.
Request Customization
Get a Sample
Get a Sample
Request Customization